

Page: Contact Information

First Name *

Last Name *

Email Address *

Phone # *

Job Title *

Have you licensed a technology in the past? *

Have you licensed any intellectual property to a company before?

Select one option

- ☐ Yes
- ☐ No

Have you started a company? *

Select one option

- ☐ Yes
- ☐ No

Have you or your institution applied to the USPTO? *

Have you filed a patent application with the United States Patent and Trademark Office?

Select one option

- ☐ Yes
- ☐ No

Research Lead

Identify the primary research lead.

Research Lead Affiliation

Research Lead Email

Clinical Lead

Identify the primary clinical lead.

Clinical Lead Affiliation

Clinical Lead Email

Business Lead

Identify the primary business lead.

Business Lead Affiliation

Business Lead Email

Page: Letter of Intent

Project Title *

Technology type *

Please select from the following three categories the one that most aligns with your technology. Note, digital health solutions (pure software, apps, etc.) are not currently suitable for the SPARK Program. If you have questions about your technology type eligibility, please contact us at sparkcu@ucdenver.edu

Select one Category

- ☐ Drug
- ☐ Device
- ☐ Diagnostic

Technology detail *

Select one option

- ☐ Biologic drug
- ☐ Small molecule drug
- ☐ Therapeutic device
- ☐ Surgical device
- ☐ Diagnostic assay
- ☐ Diagnostic device
- ☐ Research tool
- ☐ Combination product
- ☐ Other

Describe your technology if not listed above

Unmet Need *

What is the unmet need your technology is solving? (100 words max)

Solution *

What is your approach to solve this unmet need? (100 words max)

TRL *

What Technology Readiness Level ([TRL](#)) is your product at?

Select one option

- ☐ 1 Review of Scientific Knowledge Base
- ☐ 2 Development of Product Hypothesis
- ☐ 3 Identification and Characterization of Product Candidate
- ☐ 4 Optimization and Initial Demonstration of Safety and Efficacy
- ☐ 5 Advanced Characterization of Product and Initiation of Manufacturing or GLP Safety Studies
- ☐ 6 Regulated Production, Regulatory Submission, and Phase 1 Clinical Trial(s)
- ☐ 7 Scale-up, Initiation of GMP Process Validation, and Phase 2 Clinical Trial(s)
- ☐ 8 Completion of GMP Validation and Consistency Lot Manufacturing, Clinical Trials Ph3, and FDA Approval or Licensure

Years *

Number of years developing this technology

Disclosure *

Have you submitted this idea to CU Innovations previously with an [Invention Disclosure Form](#)?

Select one or more options

- ☐ Yes
- ☐ No

Patent *

Has a patent application been submitted for this technology?

Select one or more options

- ☐ Yes
- ☐ No

Trademark *

Has a trademark been registered for this technology?

Select one or more options

- ☐ Yes
- ☐ No

Copyright *

Has a copyright been granted for this technology?

Select one or more options

- ☐ Yes
- ☐ No

Case File

If known, please enter your CU Innovations case file number.

CCSTI I-Corps *

If down-selected, all three team members agree to participate in the [CCTSI I-Corps program](#) (mid-October–early November 2026, approximately 3 weeks).

Select one or more options

- ☐ Yes
- ☐ No

Innosphere Accelerator *

If selected as one of the final 5 teams, we agree to participate in the [Innosphere Life Sciences Accelerator](#) at CU Anschutz beginning winter 2027, and to submit a state (OEDIT) application by January 6, 2027.

Select one or more options

☐ Yes

☐ No